datopotamab deruxtecan

EMA backs datopotamab deruxtecan, but lung cancer access remains unclear

EMA · lung cancer · 9 min

EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.

EMA backs datopotamab deruxtecan for advanced lung cancer

EMA · lung cancer · 10 min

EMA action on datopotamab deruxtecan adds a key catalyst for lung cancer tracking, even as the program’s regulatory path differs by region. For BD teams, investors, and analysts, the story now centers on approval status, label scope, and the next clinical and filing milestones.

AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint

oncology · 8 min

AstraZeneca and Daiichi Sankyo datopotamab deruxtecan met the dual primary endpoint of progression-free survival in TROPION-Lung01, strengthening the program’s clinical case in advanced NSCLC. The readout matters for investors and BD teams because it arrives alongside an FDA-labeled EGFR-mutated NSCLC indication and a mixed breast cancer survival backdrop.

Datroway Approved: A New Hope for Metastatic TNBC Patients

FDA · metastatic TNBC · 5 min

The FDA has approved Datroway, the first TROP2-directed antibody drug conjugate, for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC). This landmark approval offers a new therapeutic avenue for a challenging patient population.